Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.
Options for non-responders to relapsing-remitting multiple sclerosis (RRMS) first-line disease-modifying therapies (DMT) are limited. We explored whether switching first-line DMT is effective. Patients with RRMS who first received interferon-beta (IFNB) or glatiramer acetate (GA) were classified in three categories: DMT change because of suboptimal response, DMT change because of other reasons, and no DMT change during follow-up. Outcomes included annualized relapse rate (ARR) and relapse-free proportions. We identified 597 patients who initiated first-line DMT. For patients who did not change DMT (n = 240), pre-DMT and on-DMT median ARR were 0.50 and 0 (P < 0.0001). At 24 months, 76% (95%CI = 69-81%) of patients who did not change DMT were relapse-free. Of the 155 who switched because of suboptimal response, 101 switched to another first-line DMT. Median ARR pre-DMT, on first DMT and second DMT were: 0.50, 0.55, and 0.25 for switchers from IFNB to GA (IFNB/GA, n = 12) (pre-DMT versus first DMT: P = 0.92; first versus second DMT: P = 0.31); 0.90, 0.50, and 0 for switchers from GA to IFNB (GA/IFNB, n = 18; P = 0.19; P = 0.01); 0.50, 0.68, and 0 for switchers from an IFNB to another IFNB (IFNB/IFNB', n = 71; P = 0.34; P = 0.02). Estimated relapse-free proportion after 24 months of treatment was 42% (95%CI=15-66%) during the period on IFNB versus 53% (95%CI = 17-80%) on GA for IFNB/GA (P = 0.21); 12% (95%CI = 0-40%) on GA versus 87% (95%CI = 59-97%) on IFNB for GA/IFNB (P = 0.001); and 41% (95%CI = 29-52%) on initial IFNB versus 67% (95%CI = 53-79%) on subsequent IFNB for IFNB/IFNB' (P = 0.0001). Switching first-line DMT in patients with RRMS failing initial therapy may be effective in many cases.